Om

Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the endocannabinoid system and G-protein-coupled receptors. Its current pipeline centers on molecules designed to address obesity, overweight, and related metabolic conditions, with lead programs including nimacimab, a peripherally restricted CB1 modulator, and SBI-100 Ophthalmic Emulsion for ocular disorders such as glaucoma. The company’s work combines antibody and formulation expertise to explore tissue-selective mechanisms aimed at metabolic and eye-health applications. Skye Bioscience serves the biotechnology and pharmaceutical sectors, where it contributes to research-driven drug development for conditions with inflammatory, fibrotic, and metabolic components. Based in San Diego, California, Skye Bioscience is positioned as a specialist developer of novel therapeutics targeting complex biological pathways.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SKYE BIOSCIENCE MED ENDAVU: Køb Skye Bioscience ($09R0) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Skye Bioscience, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.